SG Americas Securities LLC Has $672,000 Position in SpringWorks Therapeutics (NASDAQ:SWTX)

SG Americas Securities LLC lifted its stake in shares of SpringWorks Therapeutics (NASDAQ:SWTX - Free Report) by 161.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 15,235 shares of the company's stock after acquiring an additional 9,409 shares during the quarter. SG Americas Securities LLC's holdings in SpringWorks Therapeutics were worth $672,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in SWTX. Huntington National Bank lifted its stake in shares of SpringWorks Therapeutics by 38.2% in the fourth quarter. Huntington National Bank now owns 694 shares of the company's stock valued at $25,000 after buying an additional 192 shares during the period. AlphaQuest LLC raised its stake in shares of SpringWorks Therapeutics by 70.2% in the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock valued at $36,000 after buying an additional 414 shares in the last quarter. State of Wyoming boosted its position in shares of SpringWorks Therapeutics by 39.5% during the 4th quarter. State of Wyoming now owns 1,530 shares of the company's stock valued at $55,000 after acquiring an additional 433 shares in the last quarter. Barclays PLC raised its position in SpringWorks Therapeutics by 0.3% in the fourth quarter. Barclays PLC now owns 156,123 shares of the company's stock worth $5,641,000 after purchasing an additional 447 shares in the last quarter. Finally, Virtus ETF Advisers LLC boosted its holdings in SpringWorks Therapeutics by 7.4% during the fourth quarter. Virtus ETF Advisers LLC now owns 9,037 shares of the company's stock valued at $327,000 after purchasing an additional 622 shares in the last quarter.

Analyst Upgrades and Downgrades

SWTX has been the topic of several recent analyst reports. Evercore ISI lowered SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 28th. Wedbush reiterated a "neutral" rating and set a $47.00 target price (down previously from $81.00) on shares of SpringWorks Therapeutics in a research report on Monday, April 28th. HC Wainwright reissued a "neutral" rating and set a $47.00 price target (down from $74.00) on shares of SpringWorks Therapeutics in a report on Wednesday, April 30th. TD Cowen reaffirmed a "hold" rating and set a $47.00 price objective (down from $66.00) on shares of SpringWorks Therapeutics in a research note on Tuesday, April 29th. Finally, Guggenheim reaffirmed a "neutral" rating and set a $47.00 price objective on shares of SpringWorks Therapeutics in a report on Monday, May 12th. Seven research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $52.57.

SpringWorks Therapeutics Trading Down 0.0%

Shares of SpringWorks Therapeutics stock traded down $0.01 during midday trading on Tuesday, reaching $46.96. The company had a trading volume of 2,323,686 shares, compared to its average volume of 2,482,888. The stock has a fifty day simple moving average of $45.32 and a 200 day simple moving average of $44.04. SpringWorks Therapeutics has a 1-year low of $28.21 and a 1-year high of $62.00. The company has a market capitalization of $3.54 billion, a price-to-earnings ratio of -13.77 and a beta of 0.70.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative net margin of 115.60% and a negative return on equity of 51.10%. The firm had revenue of $49.09 million for the quarter, compared to analyst estimates of $64.19 million. Sell-side analysts expect that SpringWorks Therapeutics will post -2.05 earnings per share for the current year.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.